Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A9VO
|
||||
| Former ID |
DNC012301
|
||||
| Drug Name |
GYKI-52466
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Terminated | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H15N3O2
|
||||
| InChI |
InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3
|
||||
| InChIKey |
LFBZZHVSGAHQPP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7404172, 7979284, 8152239, 11111215, 11114090, 14824929, 17396037, 24277937, 29222669, 47810984, 48035358, 48259463, 49878329, 50064455, 50104854, 53789999, 57321860, 80306549, 85789031, 90341141, 99437177, 103133373, 103167505, 103978855, 104303806, 117603215, 124749873, 124757280, 124880187, 124880188, 125164084, 126407641, 126671657, 128480148, 134349506, 135062064, 142472743, 144116046, 162112768, 162221955, 162309809, 162769784, 178101027, 179149488, 198978968, 223444733, 223519189, 223653181, 224904407, 226553589
|
||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor 1 | Target Info | Inhibitor | [3] | |
| Glutamate receptor AMPA subtype | Target Info | Inhibitor | [3] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Long-term depression | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| PANTHER Pathway | Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Pathway Interaction Database | EPHB forward signaling | ||||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Trafficking of AMPA receptors | |||||
| Trafficking of GluR2-containing AMPA receptors | |||||
| Unblocking of NMDA receptor, glutamate binding and activation | |||||
| Cargo concentration in the ER | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| BDNF signaling pathway | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4210). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005470) | ||||
| REF 3 | Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70. Epub 2005 Oct 10.New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.